News

Professor David E. Thurston of the Institute of Pharmaceutical Science will lead a team at King’s to develop and optimize a range of specific small molecules for Auris

Strensiq, an innovative enzyme replacement therapy (ERT), is the first therapy approved in the U.S. for the treatment of patients with HPP, a genetic, chronic, and progressive ultra-rare

The expansion of the plant became necessary to make room for research and development, quality management, laboratory, production and logistics. 2,250 square meters of clean room space, certified

In March 2015, RedHill Biopharma acquired from Apogee the exclusive worldwide rights to YELIVA (ABC294640), a first-in-class, orally-administered sphingosine kinase-2 ("SK2") selective inhibitor. Following prior pre-clinical studies in

GDC-0310 is a selective, oral Nav1.7 small-molecule inhibitor, identified as part of the companies’ pain collaboration focused on the Nav1.7 target. Genentech has initiated a Phase 1 clinical

Merck owns both Physicians Interactive and Univadis. Financial terms of transaction were not disclosed. Univadis’s membership includes over 3 million healthcare providers in more than 90 countries. It

The expanded deal will see both the companies evaluate the safety and efficacy of a range of additional combinations across their portfolios. Lilly will lead the studies, while

The Add-Aspirin phase III trial is funded by Cancer Research UK and the National Institute for Health Research. It aims is to establish whether taking aspirin every day

Onivyde, in combination with chemotherapy drugs fluorouracil (5-FU) and leucovorin has been approved for treatment of metastatic pancreatic cancer patients who have undergone gemcitabine-based chemotherapy. The drug’s effectiveness